Some blood pressure medicine pills pose a potential cancer risk and are being recalled, the Food Drug and Administration announced. Aurobindo Pharma USA is recalling two lots of quinapril and hydrochlorothiazide tablets due to levels of nitrosamine. The tablets are commonly prescribed for the treatment of hypertension to lower blood pressure. (USA Today)

GSK dropped its regulatory plan for an arthritis drug as tests disappointed. One study for the medicine, a monoclonal antibody called otilimab, failed to meet its goal. While another two did succeed, GSK said Thursday that the efficacy demonstrated is unlikely to transform patient care. (Bloomberg)

Eli Lilly committed $92.5 million to Purdue University for pharmaceutical manufacturing scholarships. The scholarship program would provide pharmaceutical manufacturing scholarships for incoming Purdue undergraduate students worth full tuition and a guaranteed internship or co-op at Lilly, the announcement stated. (Lafayette Journal & Courier)

The World Health Organization published its first ever list of fungal infections that are ‘becoming a threat to humanity.’ The global health organization has identified 19 “priority pathogens” that include yeasts and molds and are evolving and becoming resistant to treatments. (WION)

Takeda Pharmaceutical’s latest net profit missed analysts’ expectations. Takeda’s net profit rose 34% from a year earlier to 61.7 billion yen ($421.5 million) for the quarter ended Sept. 30. That fell short of the estimate of Y84.81 billion taken from a poll of analysts by Visible Alpha. (MarketWatch)